Voyager Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
2026 is positioned as a pivotal year with major tau-targeted programs advancing, including gene therapy and antibody assets, and the first clinical use of BBB-penetrant capsids. Key data readouts and expanded partnerships are expected to drive progress in neurodegenerative disease innovation.
-
Three strategic pillars—tau-targeting, gene therapy, and NeuroShuttle—drive innovation, with two gene therapies entering the clinic and strong financial runway. Tau PET imaging is central to clinical development, and partnerships are key for advancing large-scale Alzheimer's trials.
Fiscal Year 2025
-
The company is advancing a multimodal neurotherapeutics pipeline, with a strong focus on Alzheimer's and Tau-targeted therapies, including gene therapy and antibody programs. Key assets are progressing toward clinical readouts, and strategic partnerships support expansion into additional neurodegenerative and rare disease indications.
-
The session highlighted a multimodal neurotherapeutics strategy, with a focus on Alzheimer's and Tau-targeted programs, including a pathologic-specific antibody and gene therapy entering the clinic next year. NeuroShuttle and ALPL shuttles show promise, and strong partnerships plus a $262M cash runway support upcoming milestones.
-
The company is advancing a robust neurotherapeutics pipeline, with four clinical programs expected by 2026 and a focus on validated CNS targets. Its Neuro Shuttle platform, highlighted by ALPL receptor data, aims to optimize brain delivery for diverse modalities. Cash runway extends into 2028, supporting ongoing clinical and partnered programs.
-
The conference showcased advances in CNS drug development, with a focus on multi-modality approaches and innovative delivery platforms. Key Alzheimer’s programs target tau with both antibody and gene therapy, and major partnerships are driving near-term milestones and financial strength.
-
The panel highlighted advances in neurotherapeutics, including novel AAV capsid platforms, tau-targeting programs, and emerging drug delivery strategies. Key milestones include upcoming INDs for partnered programs and a clinical proof of concept for the anti-tau antibody expected in 2026.
-
Recent data show the anti-tau antibody program advancing with strong safety and PK, and a MAD study in Alzheimer's underway. Strategic partnerships and novel capsid technology drive value, with a robust cash runway and multiple programs targeting high unmet needs.
-
SOD1 ALS gene therapy program is delayed due to payload-related neurotoxicity, with IND filing postponed as alternate payloads are sought. Other pipeline programs, including tau knockdown and Neurocrine collaborations, remain on track, and the cash runway now extends to mid-2027.
Fiscal Year 2024
-
Strong year-end cash of $332M and $8.2B in potential milestones support a robust pipeline, with key tau-targeting programs advancing and multiple clinical readouts expected in 2025-2026. Partnerships and innovative CNS delivery platforms remain central to growth.
-
The panel highlighted a robust neurogenetics pipeline, strategic partnerships, and innovative capsid technology enabling broad CNS delivery. Key programs in SOD1, tau, GBA, and FA are advancing toward clinical milestones, supported by strong financials and a focus on biomarker-driven development.
-
The discussion highlighted a robust neurogenetics pipeline targeting CNS disorders, with a strong focus on Tau-directed therapies for Alzheimer's and innovative gene therapy delivery platforms. Advancements in biomarkers, receptor-mediated delivery, and strategic partnerships are driving both clinical and business growth.
-
Pipeline advanced with key progress in anti-Tau antibody and gene therapy programs for Alzheimer's, supported by strong partnerships and a $345M cash position. Top-line safety and PK data for VY7523 expected in H1 2025, with cash runway into 2027.
-
Expanded partnerships, notably with Novartis and Neurocrine, have brought significant funding and validation, while a strong cash position supports internal and partnered programs. Three gene therapies are set to enter the clinic next year, and the tau antibody program could see key external validation in Q4.
-
The session highlighted a robust pipeline with four wholly owned and 14 partnered programs, including a new Novartis deal. Lead tau and SOD1 ALS programs are advancing toward key clinical milestones, supported by strong financials and a differentiated CNS gene therapy platform.
-
The company is advancing a robust CNS pipeline with innovative IV gene therapy technology and a strategic focus on de-risked, biomarker-driven programs. Multiple clinical readouts are expected in the next 12–18 months, supported by strong partnerships and a differentiated platform.
-
Q2 2024 saw major pipeline progress, including first-in-human dosing for the anti-Tau antibody, new gene therapy milestones, and a $100M public offering. Cash runway extends into 2027, with multiple INDs and data readouts expected in the next two years.
-
The conference showcased advances in neurogenetic medicines, highlighting a robust pipeline, expanded partnerships, and new data on CNS delivery technologies. Multiple clinical milestones are expected in the next two years, with strong financial backing and innovative approaches to CNS diseases.
-
The summit highlighted a robust pipeline targeting neurological diseases, with three gene therapy INDs planned for 2025 and a strong focus on risk mitigation through partnerships and efficient clinical design. The TRACER platform enables advanced CNS delivery, and key programs in Alzheimer's and ALS are progressing toward clinical milestones.